Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Sunday, AstraZeneca And Daiichi Sankyo's DATROWAY Extends Overall Survival By 5 Months And Reduces Progression Risk By 43% In Metastatic Triple-Negative Breast Cancer

Author: Benzinga Newsdesk | October 20, 2025 03:36am

AstraZeneca and Daiichi Sankyo's DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43% reduction in patients' risk of disease progression or death in TROPION-Breast02

DATROWAY is the first and only therapy to significantly improve overall survival vs. chemotherapy in this patient population

Posted In: AZN DSNKY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist